ATLANTA, April 18, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) (“Alimera”), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dr. Glen Bradley has joined its Board of Directors and the Audit Committee of the Board. Dr. Bradley, a consultant and advisor for ophthalmic and non-ophthalmic medical device companies, replaces Dr. Anders D. Hove, who has resigned as a member of Alimera’s Board of Directors and also as a member of the Audit Committee and Compensation Committee of the Board, effective as of April 18, 2011. Bryce Youngren, a current member of Alimera’s Board, has replaced Dr. Hove as a member of the Compensation Committee of the Board.
